Evidence map›Paper›PMID 30294717›Full record

ArticleJournal of bone research2018

Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice.

John Nguyen, Hilary Weidner, Lora M Schell, Linda Sequeira, Ryan Kabrick, Saurabh Dharmadhikari, Harold Coombs, Randall L Duncan, Liyun Wang, Anja Nohe

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Aberrant BMP2 Signaling in Patients Diagnosed with Osteoporosis.International journal of molecular sciences · 2020
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

John NguyenDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Hilary WeidnerDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Lora M SchellDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Linda SequeiraDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Ryan KabrickDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Saurabh DharmadhikariDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Harold CoombsThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Randall L DuncanDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Liyun WangDepartment of Mechanical Engineering, University of Delaware, Newark, DE 19716, USA.
Anja NoheDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
University of Delaware · USJackson Laboratory · US

Funding

Mechanism of a mimetic peptide CK2.3 on bone formationR01AR064243 · NIAMS · UNIVERSITY OF DELAWARE · PI NOHE, ANJA G · 2013 to 2018
$1.6M
NIAMS NIH HHS R01 AR064243
6 · The paper itself

Abstract

backgroundOsteoporosis is a silent disease caused by low bone mineral density that results in bone fractures in 1 out of 2 women and 1 in 4 men over the age of 50. Although several treatments for osteopenia and osteoporosis are available, they have severe side effects and new treatments are desperately needed. Current treatments usually target osteoclasts and inhibit their activity or differentiation. Treatments that decrease osteoclast differentiation and activity but enhance osteogenesis and osteoblast activity are not available. We recently developed a peptide, CK2.3, that induces bone formation and increases bone mineral density as demonstrated by injection over the calvaria of 6 to 9-day-old mice and tail vein injection of 8-week-old mice. CK2.3 also decreased osteoclast formation and activity. However, these studies raise questions: does CK2.3 induce similar results in old mice and if so, what is the effective CK2.3 concentration and, is the bone mineral density of vertebrae of the spinal column increased as well?

methodsCK2.3 was systematically injected into the tail vein of female 6-month old mice with various concentrations of CK2.3: 0.76 μg/kg, 2.3 μg/kg, or 6.9 μg/kg per mice. Mice were sacrificed one week, two weeks, and four weeks after the first injection. Their spines and femurs were collected and analyzed for bone formation.

resultsFemur and lumbar spine analyses found increased bone mineral density (BMD) and mineral apposition rate, with greater stiffness observed in femoral samples four weeks after the first injection. Histochemistry showed that osteoclastogenesis was suppressed in CK2.3 treated senile mice.

conclusionsFor the first time, this study showed the increase of lumbar spine BMD by CK2.3. Moreover, it showed that enhancement of femur BMD was accompanied by increased femur stiffness only at medium concentration of CK2.3 four weeks after the first injection indicating the maintenance of bone's structural integrity by CK2.3.

Indexed as

Bone morphogenetic proteinCasein kinase IIOsteoblastogenesisOsteoclastogenesisOsteoporosis

Identifiers

PMID30294717
PMCPMC6173331
OpenAlexW2884820213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.